Literature DB >> 24798321

The comparative clinical effectiveness and value of simeprevir and sofosbuvir for chronic hepatitis C virus infection.

Daniel A Ollendorf1, Jeffrey A Tice2, Steven D Pearson1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24798321     DOI： 10.1001/jamainternmed.2014.2151

Source DB:  PubMed          Journal:  JAMA Intern Med        ISSN： 2168-6106            Impact factor:   21.873


× No keyword cloud information.
  10 in total

Review 1.  Hepatitis C (chronic).

Authors:  Alan Hoi Lun Yau; Vladimir Marquez-Azalgara; Eric M Yoshida
Journal:  BMJ Clin Evid       Date:  2015-06-24

2.  Poor Sustained Virological Response in a Multicenter Real-Life Cohort of Chronic Hepatitis C Patients Treated with Pegylated Interferon and Ribavirin plus Telaprevir or Boceprevir.

Authors:  Kevin P Vo; Philip Vutien; Matthew J Akiyama; Vinh D Vu; Nghiem B Ha; Joy I Piotrowski; James Wantuck; Marina M Roytman; Naoky Tsai; Ramsey Cheung; Jiayi Li; Mindie H Nguyen
Journal:  Dig Dis Sci       Date:  2015-03-28       Impact factor: 3.199

3.  Meta-analysis: superior treatment response in Asian patients with hepatitis C virus genotype 6 versus genotype 1 with pegylated interferon and ribavirin.

Authors:  Nghia H Nguyen; Shelley A McCormack; Philip Vutien; Brittany E Yee; Pardha Devaki; David Jencks; Mindie H Nguyen
Journal:  Intervirology       Date:  2015-01-10       Impact factor: 1.763

4.  Assessing potential cures: are there distinctive elements of value beyond health gain?

Authors:  Saskia Hendriks; Steven D Pearson
Journal:  J Comp Eff Res       Date:  2021-03-05       Impact factor: 1.744

5.  Prices, Costs, and Affordability of New Medicines for Hepatitis C in 30 Countries: An Economic Analysis.

Authors:  Swathi Iyengar; Kiu Tay-Teo; Sabine Vogler; Peter Beyer; Stefan Wiktor; Kees de Joncheere; Suzanne Hill
Journal:  PLoS Med       Date:  2016-05-31       Impact factor: 11.069

Review 6.  Can delivery systems use cost-effectiveness analysis to reduce healthcare costs and improve value?

Authors:  Lucy A Savitz; Samuel T Savitz
Journal:  F1000Res       Date:  2016-10-25

7.  From Gutenberg to Open Science: An Unfulfilled Odyssey.

Authors:  Chris R Triggle; David J Triggle
Journal:  Drug Dev Res       Date:  2016-10-21       Impact factor: 4.360

8.  Valuing cure: bridging cost-effectiveness and coverage decisions for hepatitis C therapy.

Authors:  Mai T Pho; Benjamin P Linas
Journal:  Hepatology       Date:  2014-07       Impact factor: 17.298

9.  Minimum target prices for production of direct-acting antivirals and associated diagnostics to combat hepatitis C virus.

Authors:  Nikolien van de Ven; Joe Fortunak; Bryony Simmons; Nathan Ford; Graham S Cooke; Saye Khoo; Andrew Hill
Journal:  Hepatology       Date:  2015-02-09       Impact factor: 17.425

10.  Clinical impact of treatment timing for chronic hepatitis C infection: a decision model.

Authors:  M T Pho; D M Jensen; D O Meltzer; A Y Kim; B P Linas
Journal:  J Viral Hepat       Date:  2015-08       Impact factor: 3.517
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.